Various potential therapeutic targets have been developed for cervical cancer, including anti-EGFR, hepatocyte growth factor- (HGF/C-) met inhibitors, insulin-like growth factor (IGF/IR) targeting agents, intracellular signaling kinases, cytotoxics, PARP inhibitors, epigenetics, estrogen receptor blockers, and biologic agents [28]. Here, PARP1 is linked to cervical carcinoma.